We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by St. Claraspital AG.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00835055
First Posted: February 3, 2009
Last Update Posted: September 22, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
St. Claraspital AG
  Purpose
The purpose of this study is to determine whether markers on tumor tissue may be an indicator for good response to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Condition
Rectal Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Further study details as provided by St. Claraspital AG:

Estimated Enrollment: 100
Study Start Date: April 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
group is selected from a single institution ( community hospital)
Criteria

Inclusion Criteria:

  • locally advanced rectal cancer uT3 or uT4
  • no distant metastasis
  • neoadjuvant radiochemotherapy required

Exclusion Criteria:

  • rejection of radiochemotherapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00835055


Contacts
Contact: Beatrice Kern, MD +41 61 685858585 ext 8484 beatrice.kern@claraspital.ch

Locations
Switzerland
St. Claraspital, Chirurgische Klinik Recruiting
Basel, Switzerland, 4016
Contact: Beatrice Kern, MD    +41 61 6858585 ext 8484    beatrice.kern@claraspital.ch   
Sponsors and Collaborators
St. Claraspital AG
  More Information

Responsible Party: Dr. Urs Wagner, Viollier AG
ClinicalTrials.gov Identifier: NCT00835055     History of Changes
Other Study ID Numbers: 43/05
First Submitted: February 2, 2009
First Posted: February 3, 2009
Last Update Posted: September 22, 2009
Last Verified: September 2009

Keywords provided by St. Claraspital AG:
rectal cancer with neoadjuvant treatment
standardized clinical tests
tumor markers on tumor tissue

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases